Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

Stock Information for Scopus BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Scopus BioPharma Inc.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.